0.49
+1.04%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Yunkang Group
Its shares trade on HKEX under the ticker 2325.HK. It has been listed since 18 May 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥601.4m and net income of CN¥2.9m. At that date it held total assets of CN¥2.74bn and shareholders' equity of CN¥1.16bn.
Yunkang Group Ltd. is an investment holding company, which engages in the provision of diagnostic testing services. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2022-05-18. The firm operates three segments. Diagnosis Testing segment provides diagnosis testing to hospital and non-medical clients, mainly including routine diagnostic testing, routine pathological examination, infectious disease diagnostic testing, genetic disease diagnostic testing and early cancer detection. Hospital Management Business segment provides management services for the community clinics. Research & Development Institution segment is engaged in the research and development of testing kits. The firm primarily provides services for hospitals and other medical institutions, and commercial entities such as financial institutions and insurance companies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 18 May 2022
- Employees
- 1,931
- Website
- yunkanghealth.com ↗
Leadership
Pay as last reported
- Mr. Yong ZhangChairman of the Board, Chief Executive Officer, Executive Director
- Mr. Yingjia LinChief Financial Officer, Joint Company Secretary
- Mr. Xubo WangExecutive Vice President
- Mr. Shanghua HuVice President
- Mr. Tieding WangVice President
- Ms. Lok Yee ChanJoint Company Secretary
- Dr. Pinghui WangNon-Executive Director
- Mr. Ruihua WangNon-Executive Director
- Mr. Weijie ZhangNon-Executive Director
- Dr. Min DongNon-Executive Independent Director
- Mr. Shaohua XieNon-Executive Independent Director
- Mr. Shiyou YuNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Yunkang Group Ltd. provides diagnostic testing services to hospitals and medical institutions in Guangzhou, China.
- The company employs 1,931 full-time employees across three operational segments.
- Yunkang Group's diagnostic testing segment offers routine, pathological, and genetic disease testing services.
Weaknesses
- Yunkang Group Ltd. operates primarily within Guangzhou, limiting its national market reach.
- The company's IPO on 18 May 2022 restricts its historical financial data availability.
- Yunkang Group's focus on diagnostic testing may limit diversification in the Health Care sector.
Opportunities
- Yunkang Group can expand its diagnostic testing services to other Chinese cities beyond Guangzhou.
- The growing demand for early cancer detection services presents a significant opportunity.
- Collaborations with financial institutions and insurance companies could enhance service offerings.
Threats
- Yunkang Group faces competition from other diagnostic testing providers in Guangzhou, China.
- Regulatory changes in the Chinese Health Care sector could impact operations.
- Economic downturns in China may reduce demand for non-essential medical services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.